Cedarburg smooths the road forward - ICIS Chemical Business (May 7, 2007)
In the past three-and-a-half years, Cedarburg Pharmaceuticals has learned enough about niche generic APIs to make the recent uptick in outsourcing a particularly welcome development.
Read the full article >

Using R&D expertise to solve tough chemistry problems - sp2 (April 2007)

US chemistry process development company Cedarburg Pharmaceuticals has identified a number of process R&D opportunities in the pharmaceutical marketplace in which it can apply its considerable expertise in solving difficult chemical synthesis problems. Chuck Boland, the company's executive vice president, explains the business strategy.
Read the full article >

Cedarburg Seeks to Bounce Back with New Offering - Chemical Week (March 14, 2007)

Privately owned process development and active pharma ingredient (API) manufacturer Cedarburg Pharmaceuticals (Grafton, WI) says it has been struggling in the highly competitive generic pharmaceuticals market and so is switching its focus toward the ethical pharma market, including projects for 'virtual' pharma and major pharma.
Read the full article >

Process Development - A CMO Talks About Scale-up Issues - Contract Pharma (March 2007)

The emerging driver of the drug pipeline are virtual pharma companies. One bottleneck they face is developing a process to scale up a bench product for clinical use. Virtual pharma companies are repeating some of the same mistakes that pharma companies made in the 1980s. One such mistake is the forcefitting of what works in the lab to process development.
Read the full article >

Cedarburg Pharmaceuticals raises $3.5 million in Series A-3 financing - sp2 (March 2007)

Drug process development and API provider Cedarburg Pharmaceuticals, Inc, has raised a total of $3.5 million in a Series A-3 of preferred stock financing. Participants in the latest round include asset management company Sanders Morris Harris Group and Alfred Bader, founder of Aldrich Chemical (now Sigma- Aldrich). Cedarburg has raised $18.8 million to date since its foundation in 1997. The company recently received European approval to market cancer pain relievers Fentanyl Base and Fentanyl Citrate. The company holds Drug Master Files for both Fentanyl compounds in the USA, as well as DEA Schedule I to V licences and permits for controlled substances.
Read the full article >

Cedarburg was featured in the INFORMEX Show Daily - Informex Show Daily (Feb 14, 2007)

CEDARBURG REDEFINES VALUE

In a competitive, highly fragmented market, plenty of CMOs preach monetary value as their main selling point. But would you entrust your API with a CMO solely based on their being the lowest cost bidder?  
Read the full article >

> Ask Us For More Information
> Download a Cedarburg Brochure